BICX
BioCorRx Inc.
Healthcare · Medical Care Facilities · OID
$0.38
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
LIMITED
Data Confidence: 42.9%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$15M
Total market value of the company
Trailing P/E
N/A
Forward P/E
-7.86
Based on estimated future earnings — lower means cheaper
Rev Growth
N/A
Year-over-year revenue change
Profit Margin
N/A
How much profit the company keeps from each dollar of revenue
ROE
N/A
Return on equity — how efficiently it uses shareholder money
Analyst Target
N/A
Recommendation
NONE
Consensus view from ? analysts covering this stock
About BioCorRx Inc.

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company offers a substance use disorder recovery program, Beat Addiction Recovery, which includes cognitive behavioral therapy modules, peer support through a mobile application, and medication prescription from an independent treating physician; and the UnCraveRx weight loss management program, a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists. It also develops BICX101, an injectable and implantable naltrexone product; BICX102, a long-acting naltrexone implant that can last several months for opioid dependence and alcohol use disorders; and BICX104, a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder. The company licenses and distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. was founded in 2009 and is based in Anaheim, California.

https://www.biocorrx.com

Country: United States Industry: Medical Care Facilities
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
24.1% PASS
Debt must be below 33% of total assets
Cash Ratio
1.6% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
ACCUMULATION
Smart money appears to be building positions quietly
Sharpe Ratio
0.960
Good returns relative to risk taken
Kelly Fraction
-0.4736
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.354
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-28.1%
Historical annualised return based on price data
Max Drawdown
-79.6%
Largest peak-to-trough decline — the worst it has been
HMM State
CRISIS
Elevated risk detected — extreme caution warranted
Days in State
1
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.17
Very low correlation to market moves
52W High
$0.83
54% below the year high
52W Low
$0.20
89% above the year low
Avg Volume
979
Average daily shares traded — higher means easier to buy and sell
Short Ratio
N/A
Days it would take all short sellers to cover — higher means more crowded
Short % Float
N/A
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.19
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.00
Conservative use of debt — low financial risk
Current Ratio
0.10
Below 1 means short-term obligations exceed liquid assets — risk flag
Quick Ratio
0.05
Like current ratio but excludes inventory — stricter test
Gross Margin
97.3%
Revenue left after cost of goods — higher means pricing power
Operating Margin
353.5%
Profit from core operations before interest and tax
Free Cash Flow
$-2,274,213
Negative — the business is spending more than it generates
Revenue (TTM)
$797,244
Total revenue over the last 12 months
Net Income
$-3,440,146
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2024-12-31 LUCIDO LOUIS CHARLES President 1,428,647 —
2024-12-31 FELIX LOURDES Chief Executive Officer 752,979 —
2024-06-28 LUCIDO LOUIS CHARLES President 44,220 —
2024-06-28 INGARGIOLA LUISA Director 15,770 —
2024-06-28 FELIX LOURDES Chief Executive Officer 10,204 —
2024-05-31 LUCIDO LOUIS CHARLES President 22,831 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.